Knowledge from the 28-week extension of the LIBERTY EoE TREET fragment 3 clinical trial showed that the anti–interleukin-4/IL-13 antibody dupilumab resulted in lengthy-time period enchancment…
Extreme detrimental events remained uncommon and pores and skin remained largely optimistic in kids handled with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up…
Dupilumab (Dupixent, Sanofi and Regeneron) vastly lowered exacerbations in comparison with placebo in kids ages 6-11 years who had moderate-to-severe asthma in a fraction 3…